In our latest ‘Insights’ episode, we explore the cutting-edge advancements in artificial intelligence and its role in drug discovery and development. Vincent Bouget, Chief Scientific Officer and co-founder of Scienta Lab in Paris, shares his expertise on how their deeptech company is revolutionizing the drug discovery process in immunology and inflammation with unique, proprietary AI technology.
We discuss Scienta Lab’s innovative approach, their AI-driven technology and how it could be leveraged to accelerate drug discovery.
In 2021, I co-founded Scienta Lab, a research-driven startup, to implement precision medicine in drug development and ensure that new therapies can effectively target the right patients.
As Chief Scientific Officer, I lead our scientific vision and foster strategic partnerships with immunology research centers. At Scienta Lab, we view immuno-inflammation as a continuum of diseases driven by shared immune pathways, and our mission is to map these underlying mechanisms.
Interview with Vincent Bouget
If you like to get more intersting content please become a member or if you are already a member go to the member area directly: